Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
ICES, Toronto, ON, Canada.
Osteoporos Int. 2024 Jul;35(7):1289-1298. doi: 10.1007/s00198-024-07123-3. Epub 2024 May 17.
Little is known about the incidence of osteoporosis testing and treatment in individuals with schizophrenia, who may be more likely to fracture. Using competing risk models, we found that schizophrenia was associated with lower incidence of testing or treatment. Implications are for understanding barriers and solutions for this disadvantaged group.
Evidence suggests that individuals with schizophrenia may be more likely to experience hip fractures than the general population; however, little is known about osteoporosis management in this disadvantaged subpopulation. Our study objective was to compare bone mineral density (BMD) testing and pharmacologic treatment in hip fracture patients with versus without schizophrenia.
This was a retrospective population-based cohort study leveraging health administrative databases, and individuals aged 66-105 years with hip fracture between fiscal years 2009 and 2018 in Ontario, Canada. Schizophrenia was ascertained using a validated algorithm. The outcome was a composite measure of (1) pharmacologic prescription for osteoporosis; or (2) a BMD test. Inferential analyses were conducted using Fine-Gray subdistribution hazard regression, with mortality as the competing event.
A total of 52,722 individuals aged 66 to 105 years who sustained an index hip fracture in Ontario during the study period were identified, of whom 1890 (3.6%) had schizophrenia. Hip fracture patients with vs without schizophrenia were more likely to be long-term care residents (44.3% vs. 18.1%; standardized difference, 0.59), frail (62.5% vs. 36.5%; standardized difference, 0.54) and without a primary care provider (9.2% vs. 4.8%; standardized difference, 0.18). In Fine-Gray models, schizophrenia was associated with a lower incidence of testing or treatment (0.795 (0.721, 0.877)).
In this population-based retrospective cohort study, a schizophrenia diagnosis among hip fracture patients was associated with a lower incidence of testing or treatment, after accounting for mortality, and several enabling and predisposing factors. Further research is required to investigate barriers to osteoporosis management in this disadvantaged population.
对于患有精神分裂症的个体,骨质疏松症检测和治疗的发生率知之甚少,而他们更有可能骨折。使用竞争风险模型,我们发现精神分裂症与检测或治疗的发生率较低有关。这对于理解这一弱势群体的障碍和解决方案具有启示意义。
有证据表明,精神分裂症患者髋部骨折的风险可能高于一般人群;然而,对于这个弱势群体的骨质疏松症管理知之甚少。我们的研究目的是比较伴有和不伴有精神分裂症的髋部骨折患者的骨密度(BMD)检测和药物治疗。
这是一项回顾性基于人群的队列研究,利用健康管理数据库,纳入 2009 年至 2018 年期间在加拿大安大略省发生髋部骨折且年龄在 66-105 岁的个体。使用经过验证的算法确定精神分裂症。结局是骨质疏松症药物处方或 BMD 检测的复合指标。使用 Fine-Gray 亚分布风险回归进行推断分析,将死亡率作为竞争事件。
在研究期间,共确定了 52722 名年龄在 66 至 105 岁之间发生索引性髋部骨折的个体,其中 1890 名(3.6%)患有精神分裂症。与无精神分裂症的髋部骨折患者相比,患有精神分裂症的患者更有可能是长期护理居民(44.3%比 18.1%;标准化差异,0.59)、体弱(62.5%比 36.5%;标准化差异,0.54)和无初级保健提供者(9.2%比 4.8%;标准化差异,0.18)。在 Fine-Gray 模型中,精神分裂症与检测或治疗的发生率较低相关(0.795(0.721,0.877))。
在这项基于人群的回顾性队列研究中,在考虑到死亡率和几个使能和倾向因素后,髋部骨折患者的精神分裂症诊断与检测或治疗的发生率较低相关。需要进一步研究来调查这一弱势群体中骨质疏松症管理的障碍。